141 related articles for article (PubMed ID: 33159235)
1. The View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Cancer.
Beypinar I; Demir H; Araz M; Baykara M; Aykan NF
J Gastrointest Cancer; 2022 Mar; 53(1):57-63. PubMed ID: 33159235
[TBL] [Abstract][Full Text] [Related]
2. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.
Klingbiel D; Saridaki Z; Roth AD; Bosman FT; Delorenzi M; Tejpar S
Ann Oncol; 2015 Jan; 26(1):126-132. PubMed ID: 25361982
[TBL] [Abstract][Full Text] [Related]
3. Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study.
Alwers E; Jansen L; Bläker H; Kloor M; Tagscherer KE; Roth W; Boakye D; Herpel E; Grüllich C; Chang-Claude J; Brenner H; Hoffmeister M
Mol Oncol; 2020 Feb; 14(2):363-372. PubMed ID: 31816156
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
[TBL] [Abstract][Full Text] [Related]
5. Current status on microsatellite instability, prognosis and adjuvant therapy in colon cancer: A nationwide survey of medical oncologists, colorectal surgeons and gastrointestinal pathologists.
Toh JWT; Mahajan H; Chapuis P; Spring K
Cancer Rep (Hoboken); 2021 Feb; 4(1):e1297. PubMed ID: 33030308
[TBL] [Abstract][Full Text] [Related]
6. [Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?].
Zaanan A; Taieb J
Bull Cancer; 2019 Feb; 106(2):129-136. PubMed ID: 30527814
[TBL] [Abstract][Full Text] [Related]
7. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).
Kim JE; Hong YS; Kim HJ; Kim KP; Kim SY; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Kim JH; Kim TW
Ann Surg Oncol; 2017 May; 24(5):1289-1294. PubMed ID: 27853901
[TBL] [Abstract][Full Text] [Related]
8. Oncologic outcomes after adjuvant chemotherapy using FOLFOX in MSI-H sporadic stage III colon cancer.
Oh SY; Kim DY; Kim YB; Suh KW
World J Surg; 2013 Oct; 37(10):2497-503. PubMed ID: 23754140
[TBL] [Abstract][Full Text] [Related]
9. Medical Oncologists' Perspectives on How the Results of the IDEA Collaboration Impact the Adjuvant Treatment of Stage III Colon Cancer.
Yu IS; Pereira AAL; Lee M; Korphaisarn K; Marshall J; Segelov E; O'Callaghan C; Lim HJ; Kopetz S; Loree JM
Oncologist; 2020 Mar; 25(3):229-234. PubMed ID: 32162828
[TBL] [Abstract][Full Text] [Related]
10. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
Chouhan H; Sammour T; Thomas ML; Moore JW
J Surg Oncol; 2018 Dec; 118(8):1311-1317. PubMed ID: 30399198
[TBL] [Abstract][Full Text] [Related]
11. Microsatellite Instability and Adjuvant Chemotherapy in Stage II Colon Cancer.
Koenig JL; Toesca DAS; Harris JP; Tsai CJ; Haraldsdottir S; Lin AY; Pollom EL; Chang DT
Am J Clin Oncol; 2019 Jul; 42(7):573-580. PubMed ID: 31166206
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
Kim SH; Shin SJ; Lee KY; Kim H; Kim TI; Kang DR; Hur H; Min BS; Kim NK; Chung HC; Roh JK; Ahn JB
Ann Surg Oncol; 2013 Oct; 20(11):3407-13. PubMed ID: 23943026
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients.
Oki E; Shinto E; Shimokawa M; Yamaguchi S; Ishiguro M; Hasegawa S; Takii Y; Ishida H; Kusumoto T; Morita M; Tomita N; Shiozawa M; Tanaka M; Ozawa H; Hashiguchi Y; Ohnuma S; Tada S; Matsushima T; Hase K
BMC Cancer; 2021 Dec; 21(1):1332. PubMed ID: 34906120
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive significance of MSI in stages II/III colon cancer.
Saridaki Z; Souglakos J; Georgoulias V
World J Gastroenterol; 2014 Jun; 20(22):6809-14. PubMed ID: 24944470
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of microsatellite instability in sporadic colon cancers.
Sinicrope FA; Sargent DJ
Curr Opin Oncol; 2009 Jul; 21(4):369-73. PubMed ID: 19444104
[TBL] [Abstract][Full Text] [Related]
16. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin.
Zaanan A; Cuilliere-Dartigues P; Guilloux A; Parc Y; Louvet C; de Gramont A; Tiret E; Dumont S; Gayet B; Validire P; Fléjou JF; Duval A; Praz F
Ann Oncol; 2010 Apr; 21(4):772-780. PubMed ID: 19833818
[TBL] [Abstract][Full Text] [Related]
17. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
Lonardi S; Sobrero A; Rosati G; Di Bartolomeo M; Ronzoni M; Aprile G; Massida B; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Barni S; Zagonel V; Maiello E; Rulli E; Labianca R;
Ann Oncol; 2016 Nov; 27(11):2074-2081. PubMed ID: 27573560
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.
He EY; Hawkins NJ; Mak G; Roncolato F; Goldstein D; Liauw W; Clingan P; Chin M; Ward RL
Oncologist; 2016 May; 21(5):618-25. PubMed ID: 27009937
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
